Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 35 citing articles:

Evolution of SARS CoV-2 Omicron subvariants BF.7 and XBB.1.5: Time to follow Africa and abort all COVID restrictions
Mina Kelleni
Journal of Infection (2023) Vol. 86, Iss. 4, pp. 405-405
Open Access | Times Cited: 20
Evaluating NSAIDs in SARS-CoV-2: Immunomodulatory mechanisms and future therapeutic strategies
Said Moshawih, Qais Jarrar, Abdul Alim Bahrin, et al.
Heliyon (2024) Vol. 10, Iss. 3, pp. e25734-e25734
Open Access | Times Cited: 5
The African Kelleni’s roadmap using nitazoxanide and broad-spectrum antimicrobials to abort returning to COVID-19 square one
Mina Kelleni
Inflammopharmacology (2023) Vol. 31, Iss. 6, pp. 3335-3338
Open Access | Times Cited: 9
Green “turn-off” luminescent nanosensors for the sensitive determination of desperately fluorescent antibacterial antiviral agent and its metabolite in various matrices
Hadil M. Elbardisy, Mai M. Elnaggar, Tarek S. Belal, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 8
COVID-19 mortality paradox (United States vs Africa): Mass vaccination vs early treatment
Mina Kelleni
World Journal of Experimental Medicine (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections
Selwyn J. Hurwitz, Ramyani De, Julia C. LeCher, et al.
Viruses (2024) Vol. 16, Iss. 4, pp. 651-651
Open Access | Times Cited: 2
Real-life practice of the Egyptian Kelleni's protocol in the current tripledemic: COVID-19, RSV and influenza
Mina Kelleni
Journal of Infection (2022) Vol. 86, Iss. 2, pp. 154-225
Open Access | Times Cited: 14
NSAIDs and Kelleni’s protocol as potential early COVID-19 treatment game changer: could it be the final countdown?
Mina Kelleni
Inflammopharmacology (2021) Vol. 30, Iss. 1, pp. 343-348
Open Access | Times Cited: 16
A computational study of potential therapeutics for COVID-19 invoking conceptual density functional theory
Saloni Saloni, Dimple Kumari, Prabhat Ranjan, et al.
Structural Chemistry (2022) Vol. 33, Iss. 6, pp. 2195-2204
Open Access | Times Cited: 11
COVID-19, Ebola virus disease, and Nipah virus infection reclassification as novel acute immune dysrhythmia syndrome (n-AIDS): potential crucial role for immunomodulators
Mina Kelleni
Immunologic Research (2021) Vol. 69, Iss. 5, pp. 457-460
Open Access | Times Cited: 14
The critical impacts of cytokine storms in respiratory disorders
Shahana Riyaz Tramboo, Ahmed M. E. Elkhalifa, Syed Quibtiya, et al.
Heliyon (2024) Vol. 10, Iss. 9, pp. e29769-e29769
Open Access | Times Cited: 1
Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis
Wanting Su, Miao He, Zhaotian Guo, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 9
The Effect of Nitazoxanide on the Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Mohamed Abuelazm, Ahmed Ghanem, Ahmed K. Awad, et al.
Clinical Drug Investigation (2022) Vol. 42, Iss. 12, pp. 1031-1047
Open Access | Times Cited: 9
Home pharmacological therapy in early COVID‐19 to prevent hospitalization and reduce mortality: Time for a suitable proposal
Sergio Pandolfi, Salvatore Chirumbolo, Giovanni Ricevuti, et al.
Basic & Clinical Pharmacology & Toxicology (2021) Vol. 130, Iss. 2, pp. 225-239
Open Access | Times Cited: 11
NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory Protocol Used in Adult, Geriatric, Pediatric, Pregnant, and Immunocompromised COVID-19 Patients: A Real-World Experience
Mina Kelleni
Canadian Journal of Medicine (2021)
Closed Access | Times Cited: 10
Renin–Angiotensin System Components and Arachidonic Acid Metabolites as Biomarkers of COVID-19
Biwash Ghimire, Sana Khajehpour, Elizabeth A. Middleton, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2118-2118
Open Access | Times Cited: 3
Developing New Treatments for COVID-19 through Dual-Action Antiviral/Anti-Inflammatory Small Molecules and Physiologically Based Pharmacokinetic Modeling
Panagiotis Zagaliotis, Anthi Petrou, George A. Mystridis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 14, pp. 8006-8006
Open Access | Times Cited: 6
Potential reversal of pulmonary vasoplegia by inhaled ibuprofenate in COVID‐19 pneumonia
Christian Carlos Zurita‐Lizza, Pablo Alexis Doreski
Clinical and Translational Discovery (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 5
A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics
Thanaporn Wattanakul, Palang Chotsiri, Ivan Scandale, et al.
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 8, pp. 945-958
Open Access | Times Cited: 5
An integrated bioinformatics approach reveals the potential role of microRNA-30b-5p and let-7a-5p during SARS CoV-2 spike-1 mediated neuroinflammation
Puja Pawar, Kadambari Akolkar, Vandana Saxena
International Journal of Biological Macromolecules (2024) Vol. 277, pp. 134329-134329
Open Access
Could the next “disease X” be a pandemic of virus-induced encephalitis? What should our first medical response be?
Mina Kelleni
Expert Review of Anti-infective Therapy (2024)
Open Access
How do we change our approach to COVID with the changing face of disease?
Vasso Apostolopoulos, Jack Feehan, Vivek P. Chavda
Expert Review of Anti-infective Therapy (2024) Vol. 22, Iss. 5, pp. 279-287
Closed Access
Nipah Virus: Through a Pandemic Lens
Purva Salvi, Salonee Martins, Shalini Das, et al.
(2024), pp. 3-119
Closed Access
Diclofenac potassium/Nitazoxanide/Azithromycin Used in Adults, Children and Pregnant Patients: A Novel Potential Game Changer COVID-19 Protocol.
Mina Kelleni
(2021)
Closed Access | Times Cited: 3
NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory Protocol Used in Adults, Children and Pregnant COVID-19 Patients: An Egyptian Prospective Observational Study.
Mina Kelleni
(2021)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top